Far from even approaching the FDA for approval, NanoViricides, Inc. (NNVC) is making great strides with its anti-influenza drug candidate and penny stock. Gaining over 50% since the 10th of the month, NNVC stock is off to another strong start Thursday with over 100,000 shares traded in just the first few minutes of the session. If the positive results continue to come from their animal testing, the proposed human testing in Australia could be a major catalyst for the nano-biopharmaceutical company.
Looking for Hot Penny Stocks? Click here and get Alerts on the Best Penny Stocks FREE.
NNVC Stock Chart
Authorized: 300,000,000
Outstanding: 155,285,345 as of May 17, 2012
NanoViricides is no joke of a penny stock even though they have the typical $0 revenues since inception tag. As of March 31, 2012, the Company had $12,984,397 cash on hand and has recently gone toe-to-toe with Tamiflu® and come out of the ring with stunning results.
The Company’s anti-influenza drug candidates under its FluCide™ program, when administered orally and proven to be nearly as effective as when administered as IV injections. Two separate anti-influenza drug candidates were tested in Oral vs. IV comparison, and both displayed similar results that indicated strong oral effectiveness. The results distinctly indicated that oral administration of both of NanoViricides’ FluCide drug candidates resulted in substantially superior animal protection compared to oseltamivir (Tamiflu®), the top selection currently for influenza treatment.
Being that they are still conducting clinical trials before even approaching the FDA, further stock dilution is limited based on their current share structure. The nearly $13 million on hand as of March 31 should suffice for the Company until Q3, 2013 based on their current spending of roughly $2 million per quarter.
About NNVC Stock
NanoViricides, Inc., a nano-biopharmaceutical company, is focused on discovering, developing and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company is a development stage company with several drugs in various stages of early development, most of which are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc.
NanoViricides has the required exclusive licenses from TheraCour Pharma in perpetuity. The first agreement the Company executed with TheraCour Pharma seven years ago allowed them the exclusive, worldwide license for the treatment of the following human viral diseases:
Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.
Bottom Line: Biotech penny stocks can be huge long winners and quick short fizzlers. For now, NNVC is hot and should be treated as such. If you were to base an investment on their website, NNVC would be nothing more than a day trade at best.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)
ShareAUG
